학술논문
Fungal Endophthalmitis Associated with Compounded Products.
Document Type
Article
Author
Mikosz, Christina A.; Smith, Rachel M.; Kim, Moon; Tyson, Clara; Lee, Ellen H.; Adams, Eleanor; Straif-Bourgeois, Susanne; Sowadsky, Rick; Arroyo, Shannon; Grant-Greene, Yoran; Duran, Julie; Vasquez, Yvonne; Robinson, Byron F.; Harris, Julie R.; Lockhart, Shawn R.; Török, Thomas J.; Mascola, Laurene; Park, Benjamin J.
Source
Subject
*RETINAL diseases
*TREATMENT of eye diseases
*RETINAL surgery
*TRIAMCINOLONE acetonide
*FUSARIOSIS
*EPIDEMIC research
*THERAPEUTICS
*
*
*
*
*
*
Language
ISSN
1080-6040
Abstract
Fungal endophthalmitis is a rare but serious infection. In March 2012, several cases of probable and laboratory-confirmed fungal endophthalmitis occurring after invasive ocular procedures were reported nationwide. We identified 47 cases in 9 states: 21 patients had been exposed to the intraocular dye Brilliant Blue G (BBG) during retinal surgery, and the other 26 had received an intravitreal injection containing triamcinolone acetonide. Both drugs were produced by Franck's Compounding Lab (Ocala, FL, USA). Fusarium incarnatum-equiseti species complex mold was identified in specimens from BBG-exposed case-patients and an unopened BBG vial. Bipolaris hawaiiensis mold was identified in specimens from triamcinolone-exposed case-patients. Exposure to either product was the only factor associated with case status. Of 40 case-patients for whom data were available, 39 (98%) lost vision. These concurrent outbreaks, associated with 1 compounding pharmacy, resulted in a product recall. Ensuring safety and integrity of compounded medications is critical for preventing further outbreaks associated with compounded products. [ABSTRACT FROM AUTHOR]